In November 2023, another siRNA made its entrance to the scene of lipid-lowering molecular therapies: ARO-APOC3, a hepatocyte-targeting siRNA designed for the treatment of hypertriglyceridemia by hampering apolipoprotein C-III (APOC3) mRNA expression, a lipoprotein that inhibits triglyceride clearance by reducing lipoprotein lipase-mediated hydrolysis and hepatocyte uptake of triglyceride-rich lipoproteins [31]. Here, APOC3 is linked to hypertriglyceridemia.